Helius Medical Technologies’ (OTCMKTS:HSDT) Neutral Rating Reaffirmed at BTIG Research

BTIG Research reiterated their neutral rating on shares of Helius Medical Technologies (OTCMKTS:HSDT) in a research report released on Tuesday, June 19th. They currently have a $14.00 target price on the stock.

Shares of Helius Medical Technologies opened at $9.52 on Tuesday, according to MarketBeat. Helius Medical Technologies has a 12-month low of $7.15 and a 12-month high of $20.70.

Helius Medical Technologies (OTCMKTS:HSDT) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.08) earnings per share for the quarter.

In related news, Director Dane Andreeff purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, June 27th. The stock was acquired at an average price of $10.10 per share, with a total value of $101,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 23.00% of the stock is owned by company insiders.

About Helius Medical Technologies

Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply